Tidal Investments LLC Grows Position in Masimo Co. (NASDAQ:MASI)

Tidal Investments LLC raised its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 3,530.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,731 shares of the medical equipment provider's stock after purchasing an additional 84,342 shares during the period. Tidal Investments LLC owned approximately 0.16% of Masimo worth $14,337,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MASI. Smartleaf Asset Management LLC lifted its position in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after buying an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider's stock worth $1,622,000 after purchasing an additional 82 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider's stock valued at $1,728,000 after purchasing an additional 83 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Up 0.3%

NASDAQ MASI traded up $0.52 on Thursday, hitting $149.91. 506,566 shares of the company were exchanged, compared to its average volume of 651,960. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $8.13 billion, a PE ratio of 103.39 and a beta of 1.23. The stock has a fifty day moving average of $158.78 and a 200-day moving average of $167.39. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. The company had revenue of $372.00 million for the quarter, compared to analysts' expectations of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's revenue was down 24.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 EPS. As a group, analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $3,946,804.16. This trade represents a 29.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,053 shares of company stock worth $6,998,565 in the last ninety days. Corporate insiders own 16.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Wells Fargo & Company reduced their price objective on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Raymond James dropped their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. BTIG Research set a $193.00 target price on shares of Masimo and gave the company a "buy" rating in a research report on Wednesday, May 7th. Finally, Piper Sandler restated an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.